| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRD3550 |
| P698 | PubMed publication ID | 21959287 |
| P2093 | author name string | Cong Chen | |
| Robert A Beckman | |||
| Jason Clark | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Sources of bias in specimens for research about molecular markers for cancer | Q33628822 | ||
| Randomized clinical trials with biomarkers: design issues | Q34024227 | ||
| Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. | Q34461037 | ||
| Cancer modeling in the modern era: progress and challenges | Q34520417 | ||
| Cancer biomarkers--an invitation to the table | Q34530963 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| Bayesian clinical trials | Q36399554 | ||
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts | Q36593604 | ||
| Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 | ||
| The use of genomics in clinical trial design | Q37284262 | ||
| A comparison of phase II study strategies | Q37375886 | ||
| Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. | Q37464549 | ||
| Interim futility analysis with intermediate endpoints | Q40122830 | ||
| Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis | Q40373550 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology | Q46054107 | ||
| Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses | Q46207178 | ||
| Adaptive, group sequential and decision theoretic approaches to sample size determination | Q47324397 | ||
| The future of drug development: advancing clinical trial design. | Q51786270 | ||
| Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. | Q54220825 | ||
| Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development | Q56567839 | ||
| Investigating a sequence of randomized phase II trials to discover promising treatments | Q71540540 | ||
| Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? | Q79843510 | ||
| Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery | Q80032618 | ||
| Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients | Q81460457 | ||
| The cross-validated adaptive signature design | Q82478799 | ||
| P433 | issue | 10 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 735-748 | |
| P577 | publication date | 2011-09-30 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Integrating predictive biomarkers and classifiers into oncology clinical development programmes | |
| P478 | volume | 10 |
| Q45962274 | Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker. |
| Q42250318 | Adaptive designs for subpopulation analysis optimizing utility functions |
| Q26766584 | Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q37731264 | Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q38210285 | Can a treatment be licenced on the basis of post-treatment predictive biomarkers? |
| Q37982927 | Cancer biomarkers: selecting the right drug for the right patient |
| Q34537690 | Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor |
| Q27853182 | Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer |
| Q41110806 | Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials |
| Q44289303 | Considerations for the successful co-development of targeted cancer therapies and companion diagnostics |
| Q48187708 | Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial |
| Q56535381 | Extracting Knowledge from Failed Development Programmes |
| Q36221743 | Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer |
| Q84560475 | Incorporating biomarkers into clinical trial designs: points to consider |
| Q30412917 | Individualisation of medicine: medical philosophy and societal implications of an ambiguous guiding principle |
| Q37358959 | Long range personalized cancer treatment strategies incorporating evolutionary dynamics |
| Q28086970 | Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review |
| Q37353962 | New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs |
| Q47574086 | Optimized adaptive enrichment designs |
| Q28554393 | Optimizing Trial Designs for Targeted Therapies |
| Q37481946 | PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms |
| Q36392598 | Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing |
| Q34434447 | Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"? |
| Q26778367 | Predictive biomarkers for treatment selection: statistical considerations |
| Q38806218 | Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue |
| Q38085499 | The placebo response in medicine: minimize, maximize or personalize? |
| Q38162718 | The risks of risk aversion in drug regulation |
| Q35871069 | Third-generation sequencing techniques and applications to drug discovery |
| Q38578613 | Translating predictive biomarkers within oncology clinical development programs |
Search more.